France

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SARCLISA™ (isatuximab for injection) Now Available in Canada for Patients with Relapsed and Refractory Multiple Myeloma

Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

Therapeutic Area: Oncology Product Name: Sarclisa

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

SARCLISA™ in combination with pom-dex significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

European Commission Approves Sarclisa® (isatuximab) for Adults with Relapsed And Refractory Multiple Myeloma

Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CHMP backs Sanofi’s myeloma drug Sarclisa

Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2020

Details:

Positive CHMP opinion based on data from ICARIA-MM, the first randomized Phase 3 trial to evaluate an anti-CD38 in combination with pom-dex.

Pierre Fabre

Virtual Booth The 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group.

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Pierre Fabre receives Positive CHMP Opinion for BRAFTOVI® in Combination with Cetuximab for Treatment of BRAFV600E-mutant Colorectal Cancer

Lead Product(s): Encorafenib,Cetuximab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 01, 2020

Details:

Phase 3 BEACON CRC trial data showed that BRAFTOVI in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and reduced the risk of death by 40%.

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

Lead Product(s): Belinostat

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Acrotech Biopharma

Deal Size: $6.6 million Upfront Cash: $6.6 million

Deal Type: Agreement April 06, 2020

Details:

The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Sanofi

SARCLISA™ (isatuximab for injection) Now Available in Canada for Patients with Relapsed and Refractory Multiple Myeloma

Sanofi

European Commission Approves Sarclisa® (isatuximab) for Adults with Relapsed And Refractory Multiple Myeloma

Sanofi

CHMP backs Sanofi’s myeloma drug Sarclisa

Pierre Fabre

Pierre Fabre receives Positive CHMP Opinion for BRAFTOVI® in Combination with Cetuximab for Treatment of BRAFV600E-mutant Colorectal Cancer

Onxeo

Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC